Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
N-glycosylation by Mgat5 imposes a targetable constraint on immune-mediated tumor clearance
Erin E. Hollander, Rosemary E. Flock, Jayne C. McDevitt, William P. Vostrejs, Sydney L. Campbell, Margo I. Orlen, Samantha B. Kemp, Benjamin M. Kahn, Kathryn E. Wellen, Il-Kyu Kim, Ben Z. Stanger
Erin E. Hollander, Rosemary E. Flock, Jayne C. McDevitt, William P. Vostrejs, Sydney L. Campbell, Margo I. Orlen, Samantha B. Kemp, Benjamin M. Kahn, Kathryn E. Wellen, Il-Kyu Kim, Ben Z. Stanger
View: Text | PDF
Research Article Cell biology Oncology

N-glycosylation by Mgat5 imposes a targetable constraint on immune-mediated tumor clearance

  • Text
  • PDF
Abstract

The regulated glycosylation of the proteome has widespread effects on biological processes that cancer cells can exploit. Expression of N-acetylglucosaminyltransferase V (encoded by Mgat5 or GnT-V), which catalyzes the addition of β1,6-linked N-acetylglucosamine to form complex N-glycans, has been linked to tumor growth and metastasis across tumor types. Using a panel of murine pancreatic ductal adenocarcinoma (PDAC) clonal cell lines that recapitulate the immune heterogeneity of PDAC, we found that Mgat5 is required for tumor growth in vivo but not in vitro. Loss of Mgat5 results in tumor clearance that is dependent on T cells and dendritic cells, with NK cells playing an early role. Analysis of extrinsic cell death pathways revealed Mgat5-deficient cells have increased sensitivity to cell death mediated by the TNF superfamily, a property that was shared with other non-PDAC Mgat5-deficient cell lines. Finally, Mgat5 knockout in an immunotherapy-resistant PDAC line significantly decreased tumor growth and increased survival upon immune checkpoint blockade. These findings demonstrate a role for N-glycosylation in regulating the sensitivity of cancer cells to T cell killing through classical cell death pathways.

Authors

Erin E. Hollander, Rosemary E. Flock, Jayne C. McDevitt, William P. Vostrejs, Sydney L. Campbell, Margo I. Orlen, Samantha B. Kemp, Benjamin M. Kahn, Kathryn E. Wellen, Il-Kyu Kim, Ben Z. Stanger

×

Figure 6

Mgat5 loss augments the antitumor effects immune checkpoint blockade (ICB).

Options: View larger image (or click on image) Download as PowerPoint

Mgat5 loss augments the antitumor effects immune checkpoint blockade (I...
(A) Schematic illustrating the ICB experimental design. (B) Growth of 6694c2 EV under isotype control (n = 9), EV treated with ICB (n = 8), Mgat5-KO under isotype control (n = 8), and Mgat5-KO treated with ICB (n = 9). Spaghetti plots showing the growth of individual tumors are presented on the right. Data represent mean ± SEM. Statistical analysis by 2-way ANOVA at day 9. Not shown is significance (****) of EV + isotype ctrl and KO + ICB groups. EV + isotype ctrl and EV + ICB groups are not significantly different (P = 0.4095). (C) Survival of mice from the experiment in B. Statistical analysis by log-rank (Mantel-Cox) test. (D) Microscopic evaluation of immunofluorescent PHA-L binding in 2838c3 WT tumors treated with 1 or 2 weeks of 0 mg/kg, 1 mg/kg, or 4 mg/kg swainsonine. Quantification of immunofluorescent staining for PHA-L using ImageJ. Two mice per condition per week (EV, KO) with with 3–5 HPF per tumor. Statistical analysis done using unpaired, 2-tailed Student’s t test. (E) Growth of 2838c3 WT subcutaneous tumors in mice treated with 0 mg/kg (n = 5), 1 mg/kg (n = 4), or 4 mg/kg (n = 5) of swainsonine administered once daily i.p. for 7 days. Mice with tumors sized 20–60mm3 were enrolled in treatment. Data represent mean ± SEM. Statistical analysis by 2-way ANOVA at day 14. *P < 0.05; **P < 0.01; ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts